Prevalence and Risk Factors of Fluoroquinolone Resistance in Major Bacterial Pathogens: A Systematic Review and Meta-Analysis.

IF 3.2 Q3 MICROBIOLOGY
International Journal of Microbiology Pub Date : 2026-04-28 eCollection Date: 2026-01-01 DOI:10.1155/ijm/3173058
I Made Bayu Anggriawan, Ike Dhiah Rochmawati
{"title":"Prevalence and Risk Factors of Fluoroquinolone Resistance in Major Bacterial Pathogens: A Systematic Review and Meta-Analysis.","authors":"I Made Bayu Anggriawan, Ike Dhiah Rochmawati","doi":"10.1155/ijm/3173058","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The widespread use of fluoroquinolones for the treatment of Gram-negative bacterial infections has contributed to the rising prevalence of antimicrobial resistance. However, limited studies have systematically analyzed the prevalence of fluoroquinolone resistance (FQR) and its associated risk factors.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted, screening studies published between January 1, 2014, and October 31, 2024, from the PubMed, Medline, Embase, and CINAHL databases. Studies were included based on the following criteria: observational designs, evaluation of Gram-negative bacteria for FQR in human subjects, and investigation of FQR and associated risk factors. Data analysis, including pooled prevalence estimation and odds ratio calculation, was performed using R Studio (Version 4.2.3) with the metafor package. Heterogeneity among studies was assessed using <i>Q</i> and <i>I</i> <sup>2</sup> statistics. A funnel plot was used to assess potential publication bias among the included studies.</p><p><strong>Results: </strong>A total of 24 studies were included in the systematic review and meta-analysis. The pooled prevalence of FQR across pathogens was 35% (95% CI: 30%-40%), with species-specific rates of <i>Campylobacter</i> spp. (49%), <i>Escherichia coli</i> (35%), <i>Klebsiella</i> spp. (23%), <i>Mycobacterium tuberculosis</i> (40%), <i>Pseudomonas aeruginosa</i> (34%), <i>Proteus</i> spp. (45%), and others (26%). Subgroup analyses showed variation by fluoroquinolone generation and year of publication, with <i>E. coli</i> displaying increasing resistance trends over time. Risk factors significantly associated with FQR included the presence of an indwelling catheter, advanced age, prior hospitalization, previous fluoroquinolone or other antibiotic use, drug-resistant TB, international travel, sex, and unfavorable treatment outcomes.</p><p><strong>Discussion: </strong>Although the overall prevalence of FQR was modest, increasing trends in <i>E. coli</i> and the presence of multiple associated risk factors highlight important clinical implications. These findings emphasize the need to consider prior antibiotic use and hospitalization when guiding treatment and antimicrobial stewardship. However, these results should be interpreted with caution due to high heterogeneity and variability across the included studies.</p>","PeriodicalId":14098,"journal":{"name":"International Journal of Microbiology","volume":"2026 ","pages":"3173058"},"PeriodicalIF":3.2000,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13122566/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijm/3173058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The widespread use of fluoroquinolones for the treatment of Gram-negative bacterial infections has contributed to the rising prevalence of antimicrobial resistance. However, limited studies have systematically analyzed the prevalence of fluoroquinolone resistance (FQR) and its associated risk factors.

Methods: A systematic review and meta-analysis were conducted, screening studies published between January 1, 2014, and October 31, 2024, from the PubMed, Medline, Embase, and CINAHL databases. Studies were included based on the following criteria: observational designs, evaluation of Gram-negative bacteria for FQR in human subjects, and investigation of FQR and associated risk factors. Data analysis, including pooled prevalence estimation and odds ratio calculation, was performed using R Studio (Version 4.2.3) with the metafor package. Heterogeneity among studies was assessed using Q and I 2 statistics. A funnel plot was used to assess potential publication bias among the included studies.

Results: A total of 24 studies were included in the systematic review and meta-analysis. The pooled prevalence of FQR across pathogens was 35% (95% CI: 30%-40%), with species-specific rates of Campylobacter spp. (49%), Escherichia coli (35%), Klebsiella spp. (23%), Mycobacterium tuberculosis (40%), Pseudomonas aeruginosa (34%), Proteus spp. (45%), and others (26%). Subgroup analyses showed variation by fluoroquinolone generation and year of publication, with E. coli displaying increasing resistance trends over time. Risk factors significantly associated with FQR included the presence of an indwelling catheter, advanced age, prior hospitalization, previous fluoroquinolone or other antibiotic use, drug-resistant TB, international travel, sex, and unfavorable treatment outcomes.

Discussion: Although the overall prevalence of FQR was modest, increasing trends in E. coli and the presence of multiple associated risk factors highlight important clinical implications. These findings emphasize the need to consider prior antibiotic use and hospitalization when guiding treatment and antimicrobial stewardship. However, these results should be interpreted with caution due to high heterogeneity and variability across the included studies.

主要病原菌氟喹诺酮类药物耐药的流行及危险因素:系统综述和荟萃分析。
背景:氟喹诺酮类药物广泛用于治疗革兰氏阴性细菌感染,导致了抗菌素耐药性的上升。然而,有限的研究系统地分析了氟喹诺酮类药物耐药(FQR)的患病率及其相关危险因素。方法:对2014年1月1日至2024年10月31日在PubMed、Medline、Embase和CINAHL数据库中发表的研究进行系统评价和荟萃分析。研究纳入基于以下标准:观察设计,评估人类受试者中革兰氏阴性菌的FQR,调查FQR及其相关危险因素。使用R Studio (Version 4.2.3)和meta软件包进行数据分析,包括汇总患病率估计和优势比计算。采用Q和i2统计评估研究间的异质性。采用漏斗图评估纳入研究的潜在发表偏倚。结果:系统评价和荟萃分析共纳入24项研究。病原菌中FQR的总患病率为35% (95% CI: 30%-40%),其中弯曲杆菌(49%)、大肠杆菌(35%)、克雷伯氏菌(23%)、结核分枝杆菌(40%)、铜绿假单胞菌(34%)、变形杆菌(45%)和其他(26%)的物种特异性发病率为。亚组分析显示不同氟喹诺酮代和发表年份的差异,随着时间的推移,大肠杆菌显示出越来越多的耐药性趋势。与FQR显著相关的危险因素包括留置导尿管、高龄、既往住院、既往使用氟喹诺酮类或其他抗生素、耐药结核病、国际旅行、性别和不利的治疗结果。讨论:虽然FQR的总体流行率不高,但大肠杆菌的增加趋势和多种相关危险因素的存在突出了重要的临床意义。这些发现强调在指导治疗和抗菌药物管理时需要考虑先前的抗生素使用和住院情况。然而,由于纳入研究的高度异质性和可变性,这些结果应谨慎解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
0.00%
发文量
57
审稿时长
13 weeks
期刊介绍: International Journal of Microbiology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies on microorganisms and their interaction with hosts and the environment. The journal covers all microbes, including bacteria, fungi, viruses, archaea, and protozoa. Basic science will be considered, as well as medical and applied research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书